Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 166

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

A Phase I Study of Adenovirus-Mediated Wild-Type p53 Gene Transfer in Patients with Advanced Non-Small Cell Lung Cancer

Schuler, Martin, Rochlitz, Christoph, Horowitz, Jo Ann, Schlegel, Jens, Perruchoud, André P., Kommoss, Friedrich, Bolliger, Christoph T., Kauczor, Hans-Ulrich, Dalquen, Peter, Fritz, Mary Ann, Swanson, Steve, Herrmann, Richard, Huber, Christoph · 1998 · Human Gene Therapy

Abstract

Mutations of the tumor suppressor gene p53 are the most common genetic alterations observed in human cancer. Loss of wild-type p53 function impairs cell cycle arrest as well as repair mechanisms involved in response to DNA damage. Further, apoptotic pathways as induced by radio- or chemotherapy are also abrogated. Gene transfer of wild-type p53 was shown to reverse these deficiencies and to induce apoptosis in vitro and in preclinical in vivo tumor models. A phase I dose escalation study of a single intratumoral injection of a replication-defective adenoviral expression vector encoding wild-type p53 was carried out in patients with incurable non-small cell lung cancer. All patients enrolled had p53 protein overexpression as a marker of mutant p53 status in pretreatment tumor biopsies. Treatment was performed either by bronchoscopic intratumoral injection or by CT-guided percutaneous intratumoral injection of the vector solution. Fifteen patients were enrolled in two centers, and were treated at four different dose levels ranging from 107 to 1010 PFU (7.5 × 109 to 7.5 × 1012 particles). No clinically significant toxicity was observed. Successful transfer of wild-type p53 was achieved only with higher vector doses. Vector-specific wild-type p53 RNA sequences could be demonstrated in posttreatment biopsies of six patients. Transient local disease control by a single intratumoral injection of the vector solution was observed in four of those six successfully transduced patients. There was no evidence of clinical responses at untreated tumor sites. Wild-type p53 gene therapy by intratumoral injection of a replication-defective adenoviral expression vector is safe, feasible, and biologically effective in patients with advanced non-small cell lung cancer. Gene transfer of the human wild-type (wt) p53 tumor suppressor gene into p53 mutant tumors has been shown to have antiproliferative and apoptotic effects in vitro and in vivo. Schuler et al. report on a phase I clinical study of local wt p53 gene therapy in patients with advanced non-small cell lung cancer. A recombinant replication-deficient adenovirus carrying the complete human wt p53 cDNA under the control of the CMV immediate/early gene promoter was devised as expression vector. Gene transfer was achieved at higher virus doses without occurrence of any relevant treatment-related toxicity. In addition, clinical effects suggestive of a moderate local antiproliferative activity were observed in some patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1089/hum.1998.9.14-2075

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 166

Metadata

Authors
Schuler, M., Rochlitz, C., Horowitz, J. A., Schlegel, J., Perruchoud, A. P., Kommoss, F., Bolliger, C. T., Kauczor, H.-U., Dalquen, P., Fritz, M. A., Swanson, S., Herrmann, R., & Huber, C.
Venue
Human Gene Therapy
Published
1998-09-20
Volume
9
Issue
14
Pages
2075-2082
ISSN
  • 1043-0342 (ISSN-L)
  • 1557-7422
OpenAlex
W2021006762
Cited by
166
References
2
FWCI
11.95
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Phase I Study of Adenovirus-Mediated Wild-Type p53 Gene Transfer in Patients with Advanced Non-Small Cell Lung Cancer. https://app.cochat.ai/papers/10.1089/hum.1998.9.14-2075
The paper
Schuler, M., Rochlitz, C., Horowitz, J. A., Schlegel, J., Perruchoud, A. P., Kommoss, F., Bolliger, C. T., Kauczor, H.-U., Dalquen, P., Fritz, M. A., Swanson, S., Herrmann, R., & Huber, C. (1998). A Phase I Study of Adenovirus-Mediated Wild-Type p53 Gene Transfer in Patients with Advanced Non-Small Cell Lung Cancer. Human Gene Therapy. https://doi.org/10.1089/hum.1998.9.14-2075

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.